Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
1.630
-0.070 (-4.12%)
Mar 31, 2025, 2:37 PM EDT - Market open

Immix Biopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
11.387.414.021.230.21
Upgrade
Research & Development
11.298.744.20.130.25
Upgrade
Operating Expenses
22.6716.148.221.350.45
Upgrade
Operating Income
-22.67-16.14-8.22-1.35-0.45
Upgrade
Interest Expense
---0-0.18-0.1
Upgrade
Interest & Investment Income
1.020.57---
Upgrade
Other Non Operating Income (Expenses)
----22.76-0.57
Upgrade
EBT Excluding Unusual Items
-21.66-15.57-8.22-24.29-1.13
Upgrade
Other Unusual Items
----0.09-
Upgrade
Pretax Income
-21.66-15.57-8.22-24.38-1.13
Upgrade
Income Tax Expense
0.040.030.010.010.02
Upgrade
Earnings From Continuing Operations
-21.7-15.6-8.23-24.38-1.15
Upgrade
Minority Interest in Earnings
0.080.17---
Upgrade
Net Income
-21.61-15.43-8.23-24.38-1.15
Upgrade
Net Income to Common
-21.61-15.43-8.23-24.38-1.15
Upgrade
Shares Outstanding (Basic)
28171443
Upgrade
Shares Outstanding (Diluted)
28171443
Upgrade
Shares Change (YoY)
63.11%24.87%278.13%8.82%-
Upgrade
EPS (Basic)
-0.76-0.89-0.59-6.64-0.34
Upgrade
EPS (Diluted)
-0.76-0.89-0.59-6.64-0.34
Upgrade
Free Cash Flow
-15.77-11.42-7.41-1.59-0.4
Upgrade
Free Cash Flow Per Share
-0.56-0.66-0.53-0.43-0.12
Upgrade
EBITDA
-22.64-16.14-8.22-1.35-0.45
Upgrade
D&A For EBITDA
0.030.01000
Upgrade
EBIT
-22.67-16.14-8.22-1.35-0.45
Upgrade
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q